Food and Nutrition Grants

This funding opportunity supports businesses and non-profit organizations in Lewis County, NY, by providing financial assistance for creative projects that enhance their visibility in the community.

This funding opportunity provides support for U.S. institutions to create short-term research training programs for health professional and graduate students interested in biomedical, behavioral, or clinical research careers.

This funding opportunity provides financial support for organizations to host conferences and scientific meetings that address important public health issues relevant to the FDA's mission.

This program provides funding to early-career researchers who have received specific NIDDK K awards, enabling them to conduct small-scale research projects that will help them transition to independent investigator roles.

This funding opportunity provides financial support for early-stage researchers in the U.S. to explore innovative studies on HIV-related health issues, such as comorbidities and coinfections, with the potential to transform understanding and treatment in this field.

This grant provides access to valuable biological samples and data for researchers studying common and serious health conditions, such as diabetes and kidney diseases, to support innovative research and development of new treatments.

This funding opportunity supports research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underserved communities, while also addressing the reduction of ineffective practices.

This grant provides funding to exceptional U.S.-based graduate students transitioning from predoctoral to postdoctoral research in kidney, urologic, or hematologic sciences, encouraging diverse talent to contribute to these fields.

This funding opportunity supports researchers and organizations developing innovative therapeutic leads for diseases related to diabetes, digestive, and kidney health, focusing on early-stage preclinical validation to advance potential treatments not currently pursued by major pharmaceutical companies.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

This funding opportunity supports innovative research projects focused on understanding and advancing treatments for nonmalignant blood disorders, encouraging collaboration and involvement from new researchers in the field.

This grant provides funding for interdisciplinary research teams to explore the neural and behavioral aspects of benign urological conditions, aiming to improve understanding and treatment of these diseases.

This funding opportunity supports innovative, interdisciplinary research projects that aim to fill critical knowledge gaps and advance scientific understanding in areas related to kidney, diabetes, and digestive diseases.

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in health-related research or in the SBIR and STTR programs. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

This funding opportunity provides financial support for new researchers from diverse backgrounds to conduct small-scale health-related studies, helping them advance towards independent research careers.

This funding opportunity provides financial support for researchers to quickly evaluate new policies or programs aimed at influencing behaviors related to obesity, such as diet and physical activity, to help prevent or reduce obesity rates.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize care of persons with Type 2 diabetes from populations with health/health care disparities concordant with evidence-based guidelines. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations. Proposed projects would be expected to develop and/or test patient-centered strategies, which in addition to optimal glycemic control, would aim at completing other recommended guidelines (e.g., annual eye/foot and urine albumin exam, optimal blood pressure control, intake of ACEIs or ARBs/statin/aspirin and influenza/pneumonia vaccines).

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years.

This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build research activities in nonmalignant hematology. This Funding Opportunity Announcement (FOA) is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. This "New Directions in Hematology Research (SHINE-II)" program invites investigator-initiated grant applications for basic or early translational, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to advance new pathways for discovery. This program may include clinical research involving human subjects that is directed at understanding disease pathogenesis and prognosis. Research applications submitted under this FOA should be more limited in scope (single aim with sub-aims, as appropriate) and duration (1-3 years) than typical R01 grant applications. The SHINE-II FOA seeks specifically to promote and support new directions of research in their early stages. Applications submitted to this FOA should include preliminary data that support the conceptual basis of the research proposed and the technical approaches to be used. Moreover, while research applications submitted under this FOA are expected to be more limited in scope and shorter in duration than typical R01 applications, achievement of the research objective(s) proposed should validate novel pathways of discovery and provide the basis for future high impact research endeavors. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease. Inquiries to Scientific/Research staff prior to submission of an application to this FOA are strongly encouraged to discuss programmatic relevance and potential time tables for funding (see below, Section VII. Agency Contacts). The limited scope and shorter duration of the SHINE II R01 are not optimal for Early Stage Investigators (ESIs) and New Investigators (NIs), who should contact Scientific/Research staff prior to submission of an application to this FOA.